Price History

Hover for the daily close. The dotted line marks the period open.

Compare IVVD with… →

IVVD Key Statistics

As of Sep 4, 2026

Trading

Open: $0.82
Previous Close: $0.84
Day's Range: 0.79–0.83
52-Week Range: 0.53–3.07
Volume: 1.96M
Beta: 0.81

Valuation

Market Cap: $243.47M
P/E Ratio: unprofitable
P/S ratio: 4.17
EPS (ttm): −0.31

Financials (FY)

Revenue (FY): $53.43M+110.47%
Net Income (FY): −$52.49M
Profit margin: −183.90%
Shares Outstanding: 294.76M
1-Year Return: −17.23%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 4.80M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IVVD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−65.23%−79.34%+162.67%−88.76%+457.56%−66.56%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−66.56%
2025	+457.56%
2024	−88.76%
2023	+162.67%
2022	−79.34%
2021 (partial year)	−65.23%

As of September 4, 2026.

IVVD Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$53.43M	−$52.49M	−98.2%
2024	$25.38M	−$169.93M	−669.4%
2023	$0.00	−$198.64M	—
2022	$0.00	−$241.32M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$53.43M	$49.68M	−$55.56M	−$52.49M	−98.2%
2024	$25.38M	$23.77M	−$176.88M	−$169.93M	−669.4%
2023	$0.00	$0.00	−$207.78M	−$198.64M	—
2022	$0.00	—	−$226.26M	−$241.32M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IVVD Valuation vs Biotechnology Median

Median of 656 stocks

Metric	IVVD	Biotechnology median	vs median
P/S ratio	4.17	15.26	0.3x the median
Profit margin	−183.90%	0.00%	183.9 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Invivyd, Inc. (IVVD) is capitalised at $243.47M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 122.

Over the past 52 weeks the price has ranged from $0.53 to $3.07. IVVD last closed at $0.83 on September 4, 2026. That is −$0.01 (−1.08%) against the previous close. The latest close sits 56.44% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $53.43M. That is +110.47% against the prior fiscal year, when revenue was $25.38M. The same year closed with a net loss of $52.49M. Profit margin runs at −183.9%. That is 183.9 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $53.43M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.17. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −17.23%. Across 5 years the annualized return works out at −54.51%. Beta against the wider market is reported at 0.81. Daily returns over the trailing 5 years annualize to a volatility of 176.72%.

Growth & Income

No dividend is on file for IVVD.

2026 is still running; the price is −66.56% year to date. Across the complete calendar years on file, 2025 returned +457.56% and 2024 returned −88.76%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Invivyd, Inc. (IVVD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Invivyd, Inc.	IVVD	$243.47M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Invivyd, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Invivyd, Inc.

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Visit website →

Invivyd, Inc. (IVVD) Stock Analysis